In addition, to further evaluate the predictive value of DR in adjuvant therapy, we performed additional analysis to examine the influence of several establish high-risk factors of stage II colorectal cancer, namely, BRAF status, LVI, PNI, TB, and MSI status on ACT efficacy in patient subgroups with relevant information and compared them with the results obtained from DR analysis (21). The gene discussed is BRAF; the disease is colorectal cancer.